About
PsiThera develops oral small-molecule medicines targeting immunological and inflammatory disease proteins traditionally addressed by injected biologics, using a proprietary platform that models biologically relevant protein motion to discover druggable states.
Explore PsiThera's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.